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Elevation in liver transaminases is common in patients treated with the marine antitumor agent 
trabectedin. However, the impact of trabectedin-related transaminase elevations on treatment 
outcomes is unclear. This retrospective study investigated the correlation between liver tests 
abnormalities and treatment outcomes in patients with unresectable advanced or metastatic soft 
tissue sarcomas (STS) treated with trabectedin 1.5 mg/m2 once every 3 weeks at three reference 
centers in Italy. The effect of grade 3/4 elevations in alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) during the first two cycles and at any time during trabectedin treatment 
on progression-free survival (PFS) and overall survival (OS) were analyzed. Liver tests abnormalities 
during the first two cycles of chemotherapy or at any time during trabectedin treatment did not 
significantly affect PFS or OS. Nor were survival outcomes significantly different in the subgroups 
of patients with or without ALT/AST increases or with ALT/AST elevations ≥15 × the upper limit of 
normal (ULN) versus those with ALT/AST elevation <15 × ULN. Although liver tests abnormalities are 
common in patients treated with trabectedin, elevations in ALT and AST are usually transient, occur 
during the first two cycles of treatment, and do not appear to affect survival.
Soft tissue sarcomas (STS) are a rare group of tumors, arising predominantly from mesenchymal tissue 
with heterogeneous differentiation. They account for approximately 1% of all malignancies. Prognosis in 
advanced inoperable STS is poor, with a median survival ranging from 11 to 18 months from diagno-
sis of advanced disease1. Current treatment guidelines recommend anthracycline-based chemotherapy, 
primarily doxorubicin alone or in combination with ifosfamide, as the first-line treatment for advanced 
STS2. Therapeutic options after failure of doxorubicin and/or ifosfamide are limited.
Trabectedin (Yondelis® , PharmaMar, Spain), a cytotoxic compound isolated from the marine tunicate 
Ecteinascidia turbinata, is an active drug for the treatment of patients with locally advanced or meta-
static STS after failure of standard therapy3–6. Trabectedin, at the dose of 1.5 mg/m2 once every 3 weeks 
given as a 24-hour infusion, was approved in 2007 by the European Medicines Agency (EMA) for the 
treatment of adult patients with advanced STS, after failure of anthracyclines and ifosfamide, or who are 
unsuited to receive these agents7. Liver tests abnormalities (i.e. elevation in liver transaminases) affecting 
up to 40% of patients are among the most common adverse events (AEs) associated with trabectedin8–11. 
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Trabectedin commonly induces transient, self-limiting aspartate aminotransferase (AST)/alanine ami-
notransferase (ALT) elevations, that are easily manageable and non-cumulative10,12,13.
The objective of this study was to investigate the correlation between liver tests abnormalities and 
trabectedin efficacy in the treatment of patients with STS, by evaluating the impact of trabectedin-related 
liver adverse events on treatment outcomes.
Materials and Methods
Study design. This was an observational retrospective analysis of the data from patients with STS 
in treatment with trabectedin 1.5 mg/m2 once every 3 weeks, as a 24-hour continuous intravenous (i.v.) 
infusion, in three reference centers in Italy.
Patients. All patients enrolled in the study were ≥18 year-olds and were required to have unresect-
able advanced or metastatic, histologically proven STS measurable in accordance with the Response 
Evaluation Criteria in Solid Tumours (RECIST v.1.114). Other eligibility criteria included an Eastern 
Cooperative Oncology Group (ECOG) performance status (PS) score 0–2; adequate cardiac function, 
and adequate hematological (hemoglobin ≥9 g/dl; absolute neutrophil count ≥1.5 × 109/L; platelets 
≥100 × 109/L), renal (serum creatinine ≤1.5 mg/dL) and hepatic function [bilirubin ≤ upper limit of 
normal (ULN); AST/ALT ≤2.5 × ULN; alkaline phosphatase (AP) ≤2.5 × ULN (if total AP >2.5 × ULN, 
AP liver fraction and/or gamma glutamyltransferase and/or 5′ -nucleotidase had to be ≤ULN) and albu-
min >25 g/L].
Patients were excluded if they had any malignancy within the previous five years (except for basal cell 
carcinoma or treated cervical carcinoma in situ), or other relevant clinical conditions (active infection, 
active viral hepatitis or chronic liver disease, congestive heart failure or angina pectoris, myocardial 
infarction within the previous year, uncontrolled arterial hypertension, arrhythmias or abnormal left 
ventricular ejection fraction). Pregnant or breast-feeding women or patients not using appropriate con-
traceptive measures were excluded.
All patients were given standard steroid premedication to improve treatment tolerability, with dex-
amethasone 4 mg orally twice daily on days –1, + 1 and + 2. In addition, an i.v. bolus of 20 mg of dex-
amethasone was also administered approximately 20 minutes before the start of trabectedin infusion.
The study was conducted with the approval of Campus Bio-Medico of Rome ethical committee and 
signed informed consents were obtained from all study participants before registration. The methods 
were carried out in accordance with the approved guidelines.
Safety was evaluated in all patients receiving at least one dose of trabectedin, by assessment of adverse 
events (AEs), laboratory test results, physical examinations and vital signs. Laboratory values and AEs 
were graded according to the National Cancer Institute-Common Toxicity Criteria for Adverse Events, 
v.3.0.
Study assessments. Liver toxicity was defined as grade 3/4 elevations in alanine aminotrans-
ferase (ALT) or aspartate aminotransferase (AST) [grade 3 elevation: > 5–20 × ULN; grade 4 elevation: 
> 20 × ULN]15.
The impact of liver tests abnormalities on treatment outcomes during treatment was analyzed by 
comparing time-to-event endpoints [e.g., progression-free survival (PFS) and overall survival (OS)] of 
patients with and without grade 3/4 ALT or grade 3/4 AST elevations during the first two cycles of 
treatment with trabectedin.
The analysis also compared the survival of patients with grade 3/4 ALT and/or AST elevations occur-
ring at any time during treatment versus patients without such elevations, and of patients with peak ALT 
and/or AST elevations ≥ 15 × ULN versus patients with peak elevations < 15 × ULN.
Data were collected using a standard database (Microsoft Excel Software).
Statistical analysis. Correlation between patient characteristics and AST/ALT elevation was eval-
uated using two tailed Chi square test. Tumor response was assessed every two cycles according to 
RESCIST criteria. The disease control rate (DCR) was defined as the percentage of patients with an 
objective response and/or stable disease (SD) lasting ≥ 6 months. Progression free survival (PFS) was 
calculated as the period from the date of starting treatment to the first observation of disease progression 
or to death from any cause. The response duration was defined as the period of time from the initiation 
of treatment (in a patient responding to therapy) until documentation of radiological or symptomatic 
disease progression. The overall survival (OS) time was calculated as the period from the date of starting 
treatment until death from any cause or until the date of the last follow-up, at which point data were 
censored. PFS and OS curves were estimated by using the Kaplan-Meier method.
Stratified permutation tests were carried out to explore the association between tumor response and 
the presence of liver tests abnormalities.
The cut-off point for survival data was May 2014. SPSS software (version 17.00, SPSS, Chicago, USA) 
was used for statistical analysis. A P value of less than 0.05 was considered to indicate statistical signif-
icance.
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Results
Patient population. Data were retrospectively collected by three Italian reference centers and repre-
sented the whole number of cases treated with trabectedin with enough data on liver enzyme alteration 
(i.e., AST, ALT, Total and fractionated Bilirubin, Alkaline Phosphatase and GGT evaluated at least once 
during the interval between two consecutive and always before each following course) and sufficient 
data about follow-up and outcome (i.e., available data about radiological response and at least 6 months 
of follow-up). The analysis included a total of 113 patients, enrolled between January 2010 and June 
2014, with metastatic or locally-advanced inoperable anthracycline-pretreated STS. In this timeframe 
12 additional patients were originally included in the database but, before the final analysis, they were 
excluded for incomplete data about follow-up (n = 8) and insufficient data about liver toxicity (as pre-
viously defined).
A total of 62.8% (n = 71) and 37.2% (n = 42) of patients were male and female, respectively, with a 
median age of 57 (range: 27–79) years and with different histological subtypes of STS. The demographic 
and clinical characteristics of the study population are summarized in Table 1. A median of 4 cycles of 
trabectedin per patient were administered (range 1–32). Fifty-three patients received 6 or more cycles 
of trabectedin.
Liver function test abnormalities. No patients showed AST/ALT grade 1 elevation before receiving 
trabectedin. After two cycles of treatment with trabectedin, grade 3/4 elevations of ALT and/or AST 
were reported in 45 of 113 patients (39.82%). Grade 3 ALT and/or AST increase was observed in 33 
patients and grade 4 in 12. In the 45 patients who developed liver tests abnormalities, the median ALT 
increase was 18 × ULN (95% CI: 8–22), and the median increase of AST was 14 × UPL (95% CI: 4–19). 
39 patients had an increase of ALT and/or AST levels of more than 15 × ULN. No differences in terms 
of incidence of ALT/AST increase were detected according to basal patients features (age, sex, ECOG PS, 
number of previous chemotherapy lines, sarcoma histology).
In addition we evaluated the correlation between the presence of liver metastases and the develop-
ment of liver alteration tests and no difference was detected between patients with liver metastases and 
patient without.
Impact of elevated liver enzymes on response. Overall response rate (ORR) in the whole patient 
population was 16.8% (19 patients out of 113). However, a higher DCR was identified in 55 patients 
(48.7%). Therefore we explored the response rate according to the development of liver tests abnormalities 
Characteristic n = 113
Age, median (range), y 57 (27–79)
Gender, n (%)
 Female 42 (37.2)
 Male 71 (62.8)
Eastern Cooperative Oncology Group performance status, n (%)
 0 43 (38.1)
 1 52 (46.0)
 2 18 (15.9)
Number of prior chemotherapy regimens
 Median (range) 1 (1–6)
 ≤ 2 lines 54 (47.8)
 3 lines 45 (39.8)
 ≥ 4 lines 14 (12.4)
Tumor histology, n (%) 
 Liposarcoma 32 (28.3)
 Leiomyosarcoma 27 (23.9)
 Pleomorphic sarcoma 17 (15.0)
 Synovial sarcoma 13 (11.5)
 Other 24 (21.2)
Liver metastases at baseline, n(%)
 Yes 27 (20.3)
 No 86 (79.7)
Table 1.  Baseline demographic and clinical characteristics.
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(defined as ALT and/or AST elevation as previously described in the materials and methods section). 
In the cohort of patients with grade 3/4 ALT/AST increase (45 patients) the ORR was not statistically 
different than that observed in the remaining population (17.5% vs. 16.2%, p = 0.973). Similarly, no sta-
tistically significant difference was detected between patients who developed an increase of >15 × ULN 
of ALT/AST circulating levels (ORR: 15.4% vs. 17.6%, p = 0.976).
Even in terms of DCR, no differences were detected in both the groups of patients with grade 3/4 
ALT/AST increase and those with >15 × ALT/AST increase, in comparison with the remaining popula-
tion. In patients with grade 3/4 increase DCR was identified in 20 patients (20/45 patients; 44.4%), while 
in the cohort without grade 3/4 ALT/AST increase, DCR was detected in 55 patients (51.5%) with a P 
value of 0.590. Finally, considering the population of patients with ≥15 × ALT/AST, DCR was identified 
in 18 (18/39 patients; 46.2%) cases vs. 37 (50%) in the remaining population (p = 0.849).
Impact of elevated liver enzymes on survival. Grade 3/4 elevations in ALT/AST during the first 
two cycles of treatment with trabectedin did not significantly affect treatment outcomes in terms of 
survival. The hazard ratio (HR) for PFS and OS were not statistically significant [HR = 1.124 (95% CI: 
0.761–1.730); p = 0.734 and HR = 0.850 (95% CI: 0.513–1.190); p = 0.104, respectively] (Fig. 1). Similarly, 
when the study population was divided into patients with grade 3/4 ALT/AST elevations during treat-
ment versus those with no such abnormalities, the HRs for PFS and OS were also non-statistically sig-
nificant [HR = 0.791 (95% CI: 0.438–1.390); p = 0.309 and HR = 0.930 (95% CI: 0.679–2.007); p = 0.811, 
respectively] (Fig. 2). These findings were confirmed when the HR for PFS and for OS were calculated 
after dividing the study population into patients with peak ALT/AST elevations ≥ 15 × ULN versus 
patients with peak ALT/AST elevations <15 × ULN [HR = 0.821 (95% CI: 0.539–1.965), p = 0.227 and 
HR = 0.927 (95% CI: 0.721–2.310), p = 0.463, respectively] (Fig. 3).
Discussion
Trabectedin treatment has shown to be reasonably well tolerated during its phase II and III clinical devel-
opment. Death due to severe myelosuppression, rhabdomyolysis, acute renal failure, or respiratory failure 
attributed to treatment occurred infrequently10. The most common trabectedin-related AEs reported in 
the studies are nausea, vomiting, constipation, increases in alkaline phosphatase/AST/ALT, neutrope-
nia, anemia, thrombocytopenia, and fatigue4–6,16. Among these, grade 3/4 neutropenia and elevation of 
liver enzymes are reported as the most common toxicities related to dose delay. Although transaminase 
Figure 1. Kaplan-Meier plots of progression-free survival (a) and overall survival (b) in patients with 
grade 3/4 alanine aminotransferase (ALT) elevation during the first two cycles of trabectedin (n = 45) versus 
patients with no grade 3/4 ALT elevation (n = 68).
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increases were common with trabectedin, they followed a predictable pattern with a peak elevation at 
days 5–7 and a return to grade ≤ 1 at approximately day 15 of each cycle, and with a clear trend towards 
reduction with subsequent cycles (Fig. 4)10,17. The analysis per cycle performed in patients treated with 
the monotherapy regimen in our study showed grade 3 elevations of AST and ALT in 12% and 20% of 
cycles, respectively. Grade 4 elevations of AST and ALT occurred in 1% and 2% of cycles, respectively. 
Most transaminase elevations improved to grade 1 or to pre-retreatment levels within 15 days, and less 
than 2% of cycles had recovering times longer than 25 days. ALT and AST increases did not follow a 
cumulative pattern but showed a tendency towards less severe elevations over time. In order to manage 
liver AEs, after the first clinical experience with trabectedin, dexamethasone administration was rou-
tinely implemented to improve tolerance. Dexamethasone has been given prior to infusion at the recom-
mended dose of 20 mg 30 min in the majority of clinical studies. In addition, trabectedin dose reductions 
became mandatory in case of liver toxicity [increase in bilirubin > ULN; and/or alkaline phosphatase 
(AP) > 2.5 × ULN; and/or aminotransferases > 2.5 × ULN] between cycles that has not recovered by day 
21 of the cycle4,16. Once a dose has been reduced because of toxicity, dose escalation in the subsequent 
cycles is not recommended. If any of these toxicities reappear in subsequent cycles in a patient exhib-
iting clinical benefit, the dose may be further reduced. If more than two dose reductions are necessary, 
treatment discontinuation should be considered7.
In accordance with previous literature, patients of our study reported expected toxicities of treatment 
with trabectedin. Grade 3/4 increases of ALT were reported in about 40% of patients after the first 
two cycles of chemotherapy. These liver enzyme elevations did not have a significant impact on PFS 
(HR = 1.124; p = 0.734) and OS (HR = 0.104; p = 0.850) of the total study population. This observation 
was also confirmed in the two sub-analyses that evaluated the same outcomes in patients reporting ALT/
AST increases versus those with no increase, and in patients with ALT/AST elevations ≥15 × ULN versus 
those with ALT/AST elevation <15 × ULN.
These findings are supported by the findings of an exploratory analysis of the safety and efficacy 
outcomes in pooled data from phase II trials of single-agent trabectedin in heavily and non-heavily pre-
treated patients with recurrent ovarian cancer. No evidence for a relationship between grade 3/4 increases 
of ALT/AST during cycles 1 and 2 and efficacy outcomes was found, suggesting that early ALT/AST 
increase will not negatively affect outcomes18.
At present there are no data available in literature or specific trials evaluating the possible correlation 
between liver tests abnormalities of trabectedin and its efficacy in the treatment of STS, in terms of PFS 
and OS, which represents a strength of this study. In contrast, the retrospective nature of the study, the 
Figure 2. Kaplan-Meier plots of progression-free survival (a) and overall survival (b) in patients with 
grade 3/4 alanine aminotransferase (ALT) elevation during treatment with trabectedin (n = 54) versus 
patients with no grade 3/4 ALT elevation (n = 59).
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reduced number of patients and the heterogeneity of population represent potential limitations of the 
trial because they may have affected statistical analysis of the results. However, our study findings can 
provide useful insights into the real-world efficacy, toxicity, and management of patients treated with 
trabectedin and can represent a good hypothesis to be investigated and validated through further pro-
spective trials.
Figure 3. Kaplan-Meier plots of progression-free survival (a) and overall survival (b) in patients with 
peak alanine aminotransferase (ALT) elevation ≥ 15 × upper limit of normal (ULN) (n = 33) versus patients 
with peak alanine aminotransferase (ALT) elevation < 15 × ULN (n = 80).
Figure 4. Median alanine aminotransferase (ALT) over treatment cycles in patients with liposarcoma 
and leiomyosarcoma treated with trabectedin after failing prior anthracycline and ifosfamide treatment. 
Patients were randomized to trabectedin at a dose of 1.5 mg/m2 once every 3 weeks given as a 24-hour 
intravenous (IV) infusion or 0.58 mg/m2 weekly for 3 weeks out of 4 given as a 3-hour IV infusion. 
ULN = upper limit of normal. Data from Morgan et al. 200717.
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Conclusions
Liver tests abnormalities, defined as grade 3/4 transaminase elevations, are common events during treat-
ment with trabectedin. In most cases, AST and ALT elevations are transient and occur within the first 
two cycles of treatment. According to our current analysis, trabectedin-related liver enzymes elevations 
do not affect the progression-free or overall survival of patients.
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